Development of novel PP2A activators for use in the treatment of acute myeloid leukaemia

Title: Development of novel PP2A activators for use in the treatment of acute myeloid leukaemia
Creator: Toop, Hamish D.; Dun, Matthew D.; Ross, Bryony K.; Flanagan, Hayley M.; Verrills, Nicole M.; Morris, Jonathan C.
Relation: Organic and Biomolecular Chemistry Vol. 14, Issue 20, p. 4605-4616
Publisher Link: http://dx.doi.org/10.1039/c6ob00556j
Publisher: Royal Society of Chemistry
Resource Type: journal article
Date: 2016
Description: AAL(S), the chiral deoxy analog of the FDA approved drug FTY720, has been shown to inhibit proliferation and apoptosis in several cancer cell lines. It has been suggested that it does this by activating protein phosphatase 2A (PP2A). Here we report the synthesis of new cytotoxic analogs of AAL(S) and the evaluation of their cytotoxicity in two myeloid cell lines, one of which is sensitive to PP2A activation. We show that these analogs activate PP2A in these cells supporting the suggested mechanism for their cytotoxic properties. Our findings identify key structural motifs required for anti-cancer effects.
Subject: leukaemia; drug; cancer cell; PP2A activators
Identifier: http://hdl.handle.net/1959.13/1346236
Identifier: uon:29815
Identifier: ISSN:1477-0520
Language: eng
Full Text
Reviewed

Collections

Goal 3: Good Health and Well-Being

		Thumbnail	File	Description	Size	Format
View Details Download			ATTACHMENT02	Author final version	769 KB	Adobe Acrobat PDF	View Details Download